Journal of microbiology, epidemiology and immunobiologyJournal of microbiology, epidemiology and immunobiology0372-93112686-7613Central Research Institute for Epidemiology35710.36233/0372-9311-2019-3-22-27Antiretroviral therapy effect on specific antibodies spectrum changes to HIV-1 individual antigenes from persons infected with different virus subtypesLukhverchikL. N.Moscowfake@neicon.ruAlatortsevaG. I.Moscowfake@neicon.ruNesterenkoL. N.Moscowfake@neicon.ruDotsenkoV. V.Moscowfake@neicon.ruAmiantovaI. I.Moscowfake@neicon.ruZhukinaM. V.Moscowfake@neicon.ruKabarginaV. Yu.Moscowfake@neicon.ruBobkovaM. R.Moscowfake@neicon.ruKazennovaE. V.Moscowfake@neicon.ruZverevV. V.fake@neicon.ruMechnikov Research Institute of Vaccines and SeraGamaleya National Research Centre of Epidemiology and MicrobiologyFirst Moscow State Medical University2208201996322272108201921082019Copyright © 2019, Lukhverchik L.N., Alatortseva G.I., Nesterenko L.N., Dotsenko V.V., Amiantova I.I., Zhukina M.V., Kabargina V.Y., Bobkova M.R., Kazennova E.V., Zverev V.V.2019<p class="MsoNormal"><strong><span lang="EN-US">Aim.</span></strong><span lang="EN-US"> To estimate the antibodies (Ab) level to HIV-1 antigens in persons infected with virus various subtypes, which received and didn’t receive antiretroviral therapy (ART).</span></p><p class="MsoNormal"><strong><span lang="EN-US">Materials and methods</span></strong><span lang="EN-US">. Blood serum samples of HIV-1-infected with subtypes A1, B and C (ART+) — 40 persons, (ART-) — 29 persons. Ab were determined by modified linear immunoassay. Positivity indices for each antigen were calculated for each sample.</span></p><p class="MsoNormal"><strong><span lang="EN-US">Results</span></strong><span lang="EN-US">. Multidirectional changes in the Ab level to HIV-1 antigens were revealed in persons infected with virus various subtypes at the ART background and without it.</span></p><p class="MsoNormal"><strong><span lang="EN-US">Conclusion.</span></strong><span lang="EN-US"> The study of Ab spectrum changes in persons infected with virus various subtypes at the ART background is promising for the additional dynamic criteria development for HIV infection progress estimation.</span></p>HIV-infectionlinear immunoassayantibodiessubtype of HIV-1antiretroviral therapyВИЧ-инфекциядоктор биологических наук линейный иммуноанализдоктор биологических наук антителадоктор биологических наук субтип ВИЧ-1доктор биологических наук антиретровирусная терапия[1. Бобкова М.Р., Лаповок И.А. Лабораторные методы дифференциальной диагностики острой, ранней и текущей ВИЧ-инфекции. Кл. лаб. диагностика. 2007, 12:25-32.][2. Евстигнеев И.В. Лабораторные методы диагностики острой, ранней и текущей ВИЧ-инфекции. Кл. иммунология, аллергология, ннфектология. 2012, 4:34-40.][3. Ahmad R., Sindhu S.T, Toma E. et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 2001, 21:227-233.][4. Cohen O. J., Fauci A. S. Current strategies in the treatment of HIV infection. Adv. Intern. Med. 2001, 46:207-246.][5. Hemelaar J., Gouws E., Ghys P.D. et al. Global Trends in Molecular Epidemiology of HIV-1 during 2000-2007. AIDS. 2011, 25(5):679-689.][6. Huang J., Wang F., Argyris E. et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat. Med. 2007, 13:1241-1247.][7. Lichterfeld M. et al. Immunodominance of HrV-1-specific CD8+ T-cell responses in acute HIV-1 infection: at the corssroads of viral and host genetics. Trends in Immunol. 2005, 26:166-171.][8. Mariani R., Chen D., Schrofelbauer B. Species-specific exclusion of APOBEC3G from HIV-1 virions by vif. Cell. 2003, 114:21-31.][9. Montefiori D.C., Pantaleo G., Fink L.M. et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 1996, 173:60-67.][10. Niwa Y, Yano M., Futaki S. et al. T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120. Eur. J. Biochem. 1996, 237:64-70.][11. Pedersen C., Katzenstein T, Nielsen C. et al. Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: Relation to CD4 cell count and clinical course of primary infection. J. Acquir. Immun. Defic. Syndr. Hum. Retrovirol. 1997, 16:93-99.][12. Wang S.K., Liang P.H., Astronomo R.D. et al. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Nat. Acad. Sci. USA. 2008, 105:3690-3695.][13. Zack J.A., Arrigo S.J., Weitsman S.R. et al. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell. 1990, 61:213-222.]